RecruitingNCT05566249
A Study to Validate the Safety and Feasibility of ArtiSential in Colorectal Cancer Surgery Using Prospectively Constructed Multi-center Registry
Sponsor
Samsung Medical Center
Enrollment
1,000 participants
Start Date
Oct 1, 2022
Study Type
OBSERVATIONAL
Conditions
Summary
This study is to validate the safety and feasibility of ArtiSential (Articulating laparoscopic instrument) colorectal surgery and compare it with robotic surgery for patients with rectal cancer and rectosigmoid junction cancer.
Eligibility
Min Age: 18 YearsMax Age: 80 Years
Plain Language Summary
Simplified for easier understanding
This study is evaluating the safety and practicality of using a surgical robotic tool called ArtiSential during colorectal cancer operations. ArtiSential is an articulating laparoscopic instrument — a flexible tool used in minimally invasive surgery — and this study will track whether it is safe and feasible across multiple surgical centers.
**You may be eligible if...**
- You are between 18 and 80 years old
- You have been diagnosed with rectal cancer or rectosigmoid junction cancer confirmed by biopsy
- It is your first (primary) cancer, without distant spread
- You are scheduled for elective (planned, non-emergency) surgery with curative intent
- The surgical plan includes a low anterior resection using a double-stapled technique
**You may NOT be eligible if...**
- You are receiving systemic (full-body) chemotherapy before surgery
- Your cancer has spread to distant organs (metastatic)
- Surgery is palliative (not aiming for cure)
- Your surgery is an emergency
- You have Lynch syndrome or familial adenomatous polyposis (FAP)-related cancer
Talk to your doctor to see if this trial is right for you.
This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.
Interested in this trial?
Get notified about updates and connect with the research team.
Interventions
DEVICEArtiSential
Articulating laparoscopic instrument
Locations(1)
View Full Details on ClinicalTrials.gov
For the most up-to-date information, visit the official listing.
NCT05566249
Related Trials
Neoadjuvant Radiotherapy for Rectal Adenocarcinoma With Capecitabine Versus TAS-102 (Neo-REACT): A Multi-center, Randomized, Phase III Trial
NCT068500901 location
Low Rectal Cancer Treated With Total Neoadjuvant Therapy Plus Concurrent Tislelizumab Immunotherapy
NCT075610601 location
Neoadjuvant CAPOX With or Without Pucotenlimab Plus Selective Radiotherapy for Locally Advanced Rectal Cancer
NCT075282091 location
Administering Peripheral Blood Lymphocytes Transduced With a Murine T-Cell Receptor Recognizing the G12V Variant of Mutated RAS in HLA-A*11:01 Patients
NCT031909411 location
Watch and Wait in PD-1 Monoclonal Antibody Treated dMMR/MSI-H Distal Rectal Cancer
NCT046430411 location